For negative controls, we did not find a strong link for GLP-1 agonists and DPP-4 inhibitors with chronic lower respiratory disease, hearing loss, and lens disorders (HRs ranging from 0.97 to 1.07, p-values from 0.17 to 0.80). Here, DPP4 is linked to lower respiratory tract disorder.